A study of Moderna Inc's COVID-19 vaccine in mice lends some assurance that it will not increase the risk of more severe disease, and that one dose may provide protection against the novel coronavirus, according to preliminary data released on Friday.
Vaccine helping mice produce large amounts of antibodies against SARS-CoV-2 virus, human trials planned in 6 months.
Understanding how SARS-CoV-2, the coronavirus that causes COVID-19, can shut down people’s sense of smell could reveal more about how the virus operates.
Researchers at LSU's School of Veterinary Medicine are working on a COVID-19 vaccine that is unlike any other efforts. Rather than starting from scratch, they are building off of an already available vaccine used to protect against herpes and the flu.
Statins decrease inflammation, reduce blood clots, and may also act as antivirals. Because extreme inflammation, blood clots, and stroke are some of the most severe symptoms of COVID-19, researchers are exploring whether statins could be a readily available treatment for COVID-19.
Regeneron has begun clinical development of its anti-SARS-CoV-2 antibody combination REGN-COV2. The adaptive phase 1/2/3 clinical trials will assess the effects of the antibodies on hospitalized and nonhospitalized COVID-19 patients.
A new study reports that the condition of overactive bladder (OAB) could be associated with a different route of infection by SARS-CoV-2, the virus that causes COVID-19.
The measles vaccine will be tested against coronavirus at the Tulane Primate Research Center in an effort to quickly investigate whether the decades-old vaccine might prevent the virus from turning deadly in hospitalized patients.
The University of Pittsburgh is already working on two widely publicized COVID-19 vaccine projects, but a third effort, in partnership with Boston-based Tiba Biotech, uses a novel method of creating a molecule with synthetic RNA inside of it, which could be safer and more potent than other RNA vaccine efforts because it does not use the live coronavirus.
As part of a $250,000 yearlong grant awarded last month to the University of New Mexico by the National Cancer Institute, UNM scientists have begun testing mice for coronavirus antibodies after giving them experimental vaccines.
A discovery by University of Virginia neuroscientists that antidepressant drug Fluvoxamine may help control inflammation in the immune response system has led to a clinical trial at Washington University in St. Louis to determine if the drug could help treat COVID-19 patients.
With funding from the Fralin Life Sciences Institute at Virginia Tech, researchers James Weger-Lucarelli and Nisha Duggal, from the Virginia-Maryland College of Veterinary Medicine, are establishing a reverse genetics system for SARS-CoV-2 that will serve as the basis for vaccine design and for studying viral mutations associated with COVID-19 severity and viral transmission.
SARS-CoV-2, the virus that causes COVID-19, enlists the help of two enzymes on the surface of human cells in order to invade them. A new study suggests that a compound that inhibits both enzymes could make a highly effective treatment.
With COVID-19 cases continuing to rise around the world, scientists are doing everything they can to discover more about the virus that causes it - SARS-CoV-2 - as well as investigate potential vaccines to help us stop the spread.
Altimmune, a clinical-stage biopharmaceutical company, today announced the FDA has authorized the company to proceed with a clinical trial of T-COVID, an investigational agent for the treatment of early COVID-19.
Doctors throughout the University of Virginia Health System are putting their expertise together in the continuous effort to find a COVID-19 vaccine.
A transgenic mouse developed at Cincinnati Children’s to model the deadly childhood immune disease HLH (hemophagocytic lymphohistiocytosis) may play a key role in saving lives during the COVID-19 virus pandemic.
Genetically modified mice infected with the novel coronavirus can reproduce features observed in human patients, according to a study which may lead to a new approach for testing potential COVID-19 drugs.
More than 100 vaccine efforts are currently under way in the global push to stop the COVID-19 pandemic. Here are the top 5 most promising candidates.
Catching up on the frontrunning vaccine candidates.
U.S. immunotherapy company Inovio Pharmaceuticals said its experimental vaccine to prevent coronavirus infection produced protective antibodies and immune system responses in mice and guinea pigs.
The Jackson Laboratory is delivering a unique transgenic mouse model to the world’s research community.
As coronavirus vaccines hurtle through development, scientists urge caution over hints of success emerging from small human and animal studies.
Moderna, the Massachusetts biotechnology company behind a leading effort to create a coronavirus vaccine, announced promising early results from its first human safety tests Monday.
The Jackson Laboratory in Maine is on the verge of supplying a much-needed animal for SARS-CoV-2 research.
